dofetilide, sotalol
DISEASE INTERVENTION COMPARISON RESULTS
Drugs. 1999 Dec;58(6):1043-59 Review (Narrative)
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
J Am Coll Cardiol. 2000 Feb;35(2 Suppl. A):154A-155A Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To mortality at 1 year
Circulation. 1998 Oct 27;98(17):66 Suppl. 13-14 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Circulation. 1998 Oct 27;98(17):3326 Suppl. I-633 Randomized Controlled Trial
IN StudyID: EMERALD 1998 (subordinated publication), atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is undefined Than
placebo
To AF recurrence, adverse effects, pro-arrhythmia - at 6 months
Accessed 2010 August 10 at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20-931_Tikosyn.cfm Randomized Controlled Trial
IN StudyID: EMERALD 1998, atrial fibrillation The Use of
dofetilide, sotalol
As Treatment, Chronic
Is better Than
placebo
To reduce, at 1 year, AF recurrence. But they did not modified mortality and both increased adverse events and pro-arrhythmia